

IRIS A_{per}TO



UNIVERSITÀ
DEGLI STUDI
DI TORINO

This is the author's final version of the contribution published as:

Cilloni D1, Andreani G1, Dragani M1, De Gobbi M1, Saglio G1.

Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature.

Leuk Lymphoma. 2020 Jan;61(1):234-236. doi: 10.1080/10428194.2019.1660969.
Epub 2019 Sep 10.

The publisher's version is available at:

[<https://www.tandfonline.com/doi/abs/10.1080/10428194.2019.1660969?journalCode=ilal20>]

When citing, please refer to the published version.

Link to this full text:

[inserire l'handle completa, preceduta da <http://hdl.handle.net/>]

iris-AperTO

Severe Aplastic Anemia (SAA) is characterized by immune-mediated bone marrow hypoplasia and pancytopenia and can be effectively treated with immunosuppressive therapy [1], mainly based on antithymocyte globulin (ATG) and cyclosporine or with allogeneic stem cell transplantation [2]. One third of patients is refractory to immunosuppression, with persistent severe cytopenia and transfusion requirement [1].

Eltrombopag (ELT) is an orally bioavailable thrombopoietin receptor (TPO-R) agonist approved for the treatment of aplastic anemia after an insufficient response to initial immunosuppressive therapy.

Eltrombopag demonstrated activity as single-agent in this patient population, allowing up to 50% of patients to recover blood counts and to achieve transfusion independence thus confirming the clinical benefit of this approach [3,4].

Eltrombopag has also been combined to standard horse ATG plus cyclosporine in first line, resulting in impressive overall response rate, about 90%, and a complete response rate of 40% [5]. Interestingly, best results were observed when all drugs were started simultaneously [5].

Eltrombopag exhibits several actions on hematopoietic stem cells by distinct mechanisms, the main is related to the binding of TPO receptor C-MPL, but it is demonstrated that it activates other signaling pathways in megakaryocytes (MK) such as STAT3, ERK and AKT [6,7].

Furthermore, Eltrombopag, by binding the TPO receptor c-MPL, at a position distinct from the extracellular binding site of TPO, bypasses this inhibition induced by interferon- γ (IFN- γ), a pro-inflammatory cytokine, that is implicated in human hematopoietic stem and progenitor cell depletion in immune-mediated bone marrow failure syndromes [8].

It was shown that Eltrombopag, besides the known activity on the TPO receptor also decreases labile iron within the cells [9,10]. Eltrombopag chelates both extra and intra cellular calcium and iron and can shuttle iron out of cells. The iron chelating action of eltrombopag causes anti-proliferative effects on leukemic cells lines [11]. The chelation property can partially explain the differences observed between eltrombopag and other TPO mimetic drugs.

We report here a case of a patient affected by SAA who obtained complete hematological response when the iron chelator deferasirox was added to eltrombopag therapy.

Clinical case

A female patient, 67 yrs old, was diagnosed with SAA in June 2015. Her blood count was: white blood cells (WBC) $2.14 \times 10^9/L$, neutrophils $0.4 \times 10^9/L$, Hb 9 gr/dL, reticulocytes $20 \times 10^9/L$, platelets (PLT) $7 \times 10^9/L$, serum ferritin was 388 ng/mL. Virus infections by Hepatitis B (HBV) and C (HCV), Epstein Barr (EBV), Cytomegalovirus (CMV), Parvovirus and Human Immunodeficiency Virus (HIV) were excluded. Anti nuclear antibodies and anti double strand DNA were negative. Bone marrow aspirate and biopsy showed a picture of aplastic anemia with an empty marrow and a cellularity less than 10%. Cytogenetic analysis was normal. She was treated with steroids and then with cyclosporine and four doses of

thymoglobuline at the dose of 250 mg/day. After 4 months of immunosuppressive therapy the blood count was unchanged, the transfusion requirement was 4 platelets units and 6 RBC units/month. The serum ferritin was 3005 ng/mL, transferrin saturation was 57%. In September 2015 she started eltrombopag at escalating doses from 25 mg/day to 150 mg/day.

In December 2015, after 3 months of eltrombopag therapy the blood count was: WBC $3.4 \times 10^9/L$ neutrophils $0.9 \times 10^9/L$, Hb 8,6 gr/dL, PLT $6 \times 10^9/L$. PLT transfusion requirement was stable and RBC transfusion requirement was slightly reduced (2 RBC U/month) and the serum ferritin level was 5506 ng/mL.

In December 2015 she started deferasirox at the dose of 10 mg/kg/day. After 1 month of deferasirox and eltrombopag therapy (January 2016) the WBC were $4.5 \times 10^9/L$, neutrophils $2.1 \times 10^9/L$, Hb 9,7 gr/dL, PLT $22 \times 10^9/L$. She obtained transfusion independence (Figure 1). The Hb and platelet counts progressively increased, in March 2016 the WBC were $4.4 \times 10^9/L$, Hb 11,2 gr/dL, PLT $29 \times 10^9/L$. In March 2016 she suspended Deferasirox for gastrointestinal intolerance. After 2 weeks of suspension the blood count was: WBC $2.8 \times 10^9/L$, neutrophils $0.87 \times 10^9/L$, Hb 8,2 gr/dL, PLT $12 \times 10^9/L$. She restarted transfusions of both RBC and PLT.

In May 2016 she restarted deferasirox at the dose of 10 mg/kg and she obtained again RBC and PLT transfusion independence and after 3 weeks the blood count was: WBC $3.66 \times 10^9/L$, neutrophils $1.3 \times 10^9/L$, Hb 11,2 gr/dL, PLT $31 \times 10^9/L$.

In July 2016, she discontinued deferasirox for gastrointestinal intolerance. After 2 weeks PLT and Hb decreased (PLT $13 \times 10^9/L$ and Hb 9 gr/dL). She restarted deferasirox in and the blood count increased again and she obtained again transfusion independence.

From July 2016 until April 2017 the blood count progressively improved until completely normal values: WBC $6.9 \times 10^9/L$, neutrophils $3.1 \times 10^9/L$ Hb 13,8 and PLT $152 \times 10^9/L$.

In July 2017 she stopped deferasirox when the serum ferritin was 501 ng/mL. In 2018 she progressively reduced eltrombopag dose from 150 mg to 25 mg/day.

At the moment we are writing, after 40 months of eltrombopag therapy and 18 months from deferasirox suspension the patient is in complete remission with a normal blood count.

She is currently under eltrombopag therapy at the dose of 25 mg twice a week. Her blood count is: WBC $6.76 \times 10^9/L$, neutrophils $3.68 \times 10^9/L$, Hb 14,1 gr/dL and PLT $201. \times 10^9/L$.

Hematological responses in patients with SAA have been reported during iron chelation therapy (ICT) in many studies [12–14]. In principle, some beneficial effects of eltrombopag on hematopoiesis in aplastic anemia, could also derive from its property to remove iron. Many case reports indicate that iron chelation can improve hematopoiesis. In 2008 Park and colleagues [12] reported a case of a 16-yr-old patient affected by SAA and secondary hemochromatosis due to red blood cell transfusions. He was diagnosed with aplastic anemia at 11-yr of age. After five years of transfusions he developed a dilated cardiomyopathy, multiple endocrine and liver dysfunction, generalized bleeding and skin pigmentation. He started regular iron chelation therapy with deferoxamine, His cytopenia and organ dysfunctions gradually recovered until he completely normalized the peripheral blood cell

count. Following these observations with deferoxamine many cases have been reported with oral iron chelator deferasirox.

In 2010 Koh and colleagues [13] reported two children with SAA and high transfusion requirement with iron overload who received iron chelation therapy with deferasirox. In one of them the restoration of trilineage hematopoiesis and consequent transfusion independence was observed in parallel with the reduction of serum ferritin level. In 2011 Lee and colleagues [14] reported a case of a child with SAA who, 7 years after diagnosis, was enrolled in a trial of iron chelation with deferasirox. He obtained a hematological improvement and transfusion independence.


In 2013 Lee and colleagues [15] reported the post hoc analysis of the EPIC trial, a prospective study enrolling patients with chronic anemia and iron overload due to chronic red blood cell transfusions.

The analysis was conducted on a sub-cohort of 116 patients with aplastic anemia. The hematologic responses were analyzed in 72 patients with evaluable hematologic parameters. Twenty-four patients received deferasirox without concomitant immunosuppressive treatment. Partial hematologic responses were observed in 11 of 24 (45.8%) patients; all became transfusion-independent. One patient had an additional platelet response and one patient had an additional platelet and hemoglobin response. The responses were associated with a significantly reduction of serum ferritin level.

At present, to the best of our knowledge, there are no cases reported in literature of patients with aplastic anemia treated with eltrombopag associated with deferasirox.

This case strongly suggests the possibility that deferasirox may improve eltrombopag response, probably by removing toxic iron. This observation requires further investigation but it may stimulate clinicians to pay attention to this effect.

Figure 1. Hb and PLT count over time during eltrombopag (ELT) and deferasirox (DFX) therapy.



Authors contributions

DC collected data and wrote the manuscript.

GA, MDr, MDe and GS collected data and provided final approval.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

1. Young NS. Aplastic anemia. *N Engl J Med*. 2018;379(17):1643–1656.
2. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. *Blood*. 2007;109(10):4582–4585.
3. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. *N Engl J Med*. 2012;367(1):11–19.
4. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. *Blood*. 2014;123(12):1818–1825.
5. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. *N Engl J Med*. 2017;376(16):1540–1550.
6. Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. *Blood*. 2009;114(18):3899–3908.
7. Sun H, Tsai Y, Nowak I, et al. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. *Stem Cell Res*. 2012;9(2):77–86.
8. Alvarado LJ, Huntsman HD, Cheng H, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN- γ . *Blood*. 2019;133(19):2043–2055.
9. Zhao Z, Sun Q, Sokoll LJ, et al. Eltrombopag mobilizes iron in patients with aplastic anemia. *Blood*. 2018;131(21):2399–2402.
10. Vlachodimitropoulou E, Chen YL, Garbowski M, et al. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. *Blood*. 2017;130(17):1923–1933.
11. Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. *Blood*. 2012;120(2):386–394.
12. Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. *J Korean Med Sci*. 2008;23(2):320–323.
13. Koh KN, Park M, Kim BE, et al. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia. *J Pediatr Hematol Oncol*. 2010;32(8):611–614.
14. Lee JW, Jang PS, Chung NG, et al. Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia. *Pediatr Hematol Oncol*. 2011;28(8):718–720.
15. Lee JW, Yoon SS, Shen ZX, et al. Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. *Haematologica*. 2013;98(7):1045–1048.

This full text was downloaded from iris-AperTO: <https://iris.unito.it/>